2
Orphan Designations
0 approved, 1 designated
1
FDA Approvals
Latest: NERLYNX (2017)
0
Active Trials
200 recruiting
2
Rare Diseases
across 5 areas
0
News (30d)
Quiet
Puma Biotechnology, Inc. is a company with 2 orphan drug designations across 2 rare diseases, including 1 FDA-approved therapy. 1 active policy bill affects their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| breast cancer | neratinib | Des.TrialAppr. |
| small cell lung carcinoma | alisertib | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
7
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
1
affecting portfolio
0% of portfolio targets high unmet need diseases
7
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
1
affecting portfolio